# Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

> **NCT00509379** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie** · enrollment: 48 (actual)

## Conditions studied

- Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** VELCADE

## Key facts

- **NCT ID:** NCT00509379
- **Lead sponsor:** Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-11
- **Final completion:** 2011-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509379, "Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00509379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*